During clinical trials, the most frequently reported adverse event in the BenzaClin (clindamycin and benzoyl peroxide) treatment group was dry skin (12%). The Table below lists local adverse events reported by at least 1% of patients in the BenzaClin (clindamycin and benzoyl peroxide) and vehicle groups.
Local Adverse Events - all causalities in > /= 1% of patients
n = 420
n = 168
|Application site reaction||13 (3%)||1 ( < 1%)|
|Dry skin||50 (12%)||10 (6%)|
|Pruritus||8 (2%)||1 ( < 1%)|
|Erythema||6 (1%)||1 ( < 1%)|
The actual incidence of dry skin might have been greater were it not for the use of a moisturizer in these studies.
Anaphylaxis, as well as allergic reactions leading to hospitalization, have been reported during post-marketing use of clindamycin/benzoyl peroxide products. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.